Expert Analysis

Chronic Lymphocytic Leukemia/Chronic Myeloid Leukemia

Source: CCO Independent Conference Coverage of the American Society of Hematology 2008 Annual Meeting*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Chronic Lymphocytic Leukemia/Chronic Myeloid Leukemia

Program Director: Roy A. Beveridge, MD

Faculty:

Brian Druker, MD
Kanti Rai, MD
William G. Wierda, MD, PhD

Allen S. Yang, MD, PhD

CREDIT INFORMATION

Release Date: 03/06/09

Expiration Date: 03/05/10

Physicians: maximum of 1.25 AMA PRA Category 1 Credits™

Registered Nurses: 1.3 Nursing contact hours

Pharmacists: 1.3 contact hours (0.13 CEUs)

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Summarize the results of recent studies of the use of approved and investigational agents for the treatment of CLL
Recount findings from recent studies evaluating the use of approved and investigational agents for treating CML
Detail new developments in the management of adverse events related to the treatment of CML and CLL

Topics covered include:

Fludarabine/Cyclophosphamide Plus Rituximab vs Fludarabine/Cyclophosphamide in Frontline and Relapsed/Refractory Chronic Lymphocytic Leukemia
Bendamustine Plus Rituximab in Frontline CLL
Lenalidomide in the Treatment of CLL
Ofatumumab for Treatment of Fludarabine-Refractory CLL
Frontline Imatinib in CML
Dasatinib and Nilotinib in the Treatment of CML
Imatinib in Combination With Interferon or Ara-C in Frontline CML
Discontinuation of Imatinib for Patients With CML
Allogeneic Hematopoietic Stem Cell Transplantation in the Imatinib Era
Conclusions

Abstract

Click here to view abstract

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.